A Phase 3 interventional study of Telaprevir and Pegylated-interferon-alfa-2a in Genotype 1 Chronic Hepatitis C, sponsored by Janssen-Cilag International NV. Completed at 5 sites in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-01-30.
Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing telaprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. telaprevir · Hepatitis C.
Among the 39 studies testing telaprevir in Hepatitis C, this one is the 17th largest by enrollment, is one of 12 that started in 2012, is one of 13 in phase 3, and was the 24th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →None of the 39 studies testing telaprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →
telaprevir: first FDA approval 2011 (INCIVEK), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 9 · Phase 3 13 · Phase 4 5
First in 2005; this study’s year is marked. 12 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 30 across the 39 interventional studies. Of the 37 that completed or were terminated, 20 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag International NV, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag International NV is the lead sponsor of 67 studies on the registry; none are open to participants now.
66 studies in Hepatitis C by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 65 finished, 17 (26%) have results posted.
Among the 66 studies in Hepatitis C by Johnson & Johnson, this one is the 33rd largest by enrollment of the 61 interventional ones that give a count, is one of 11 that started in 2012, is one of 16 in phase 3, and was the 49th registered.
Johnson & Johnson’s Hepatitis C studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing telaprevir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 66 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the effectiveness, safety and tolerability of telaprevir administered as 750 mg every 8 hours (q8h) in combination with pegylated interferon (Peg-IFN)-alfa-2a and ribavirin (RBV) in treatment-naïve and treatment-experienced Russian participants with genotype 1 chronic hepatitis C.
This is an open-label (all persons know the study drug assignment), multicenter study in treatment-naïve (participant did not receive any previous treatment for the treatment of hepatitis C) and treatment-experienced (participant did receive previous treatment for hepatitis C) Russian participants with genotype 1 chronic hepatitis C. After a screening period of approximately 4 weeks, participants will be treated for 12 weeks with telaprevir 750 mg every 8 hours in combination with Peg-IFN-alfa-2a and RBV followed by 12 or 36 weeks of treatment with Peg-IFN-alfa-2a and RBV alone depending on their liver disease status, response to previous treatment and individual virologic response during treatment in this study. After the treatment period, there is a follow-up phase of at least 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment naïve participants will receive telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual ontreatment virologic response in this study.
Drug: Telaprevir · Drug: Pegylated-interferon-alfa-2a · Drug: Ribavirin
Treatment-experienced participants received telaprevir 750 mg 8 hourly for 12 weeks in combination with Peg-IFN alfa-2a 180 microgram weekly and RBV 1000 - 1200 mg daily (dependent on weight) for 24 or 48 weeks. Total treatment duration will be based on participant's prior treatment status, liver disease status, and individual on-treatment virologic response in this study.
Drug: Telaprevir · Drug: Pegylated-interferon-alfa-2a · Drug: Ribavirin
Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is \< 75kg) or 1200mg (if participant's weight is \>= 75kg) per day for 24 or 48 weeks.
Number of Participants With Extended Rapid Virologic Response (eRVR)
A eRVR is defined as having hepatitis C virus (HCV) ribonucleic acid (RNA) less than 25 IU/mL, (target not detected) at Weeks 4 and 12 of treatment.
Time frame: Week 4 and Week 12
Median Change in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
Changes from baseline in log10 HCV RNA levels were calculated.
Time frame: Baseline (Week 0), Week 4, Week 8, Week 12, Week 24, Week 32, Week 40, and Week 48
Number of Participants With Rapid Virologic Response (RVR) at Week 4
A RVR is defined as having hepatitis C virus (HCV) ribonucleic acid (RNA) less than 25 IU/mL, (target not detected) at Week 4
Time frame: Week 4
Number of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Less Than 25 IU/mL, (Target Not Detected) at Weeks 8, 12, 24, 32, 40 and 48
The table below shows number of participants with HCV RNA Less than 25 IU/mL, (target not detected) at Weeks 8, 12, 24, 32, 40 and 48. Only 3 treatment-naive and 14 Treatment-experienced participants were assigned to receive study treatment after Week 24. Only participants still receiving Treatment were assessed at 32, 40, and 48 weeks.
Time frame: Weeks 8, 12, 24, 32, 40 and 48
Number of Participants With Virologic Failure
Virologic failure is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) levels more than 1,000 IU/mL at Weeks 4, 8, 12, 24, 32, or 40.
Time frame: Week 4, Week 8, Week 12, Week 24, Week 32, or Week 40
Number of Participants in Each Specific Category of Treatment Outcome
Participants were evaluated for following 4 categories of treatment outcome;Sustained Virologic Response 12 Weeks After Last Planned Dose of Study Medication(SVR12):hepatitis C virus (HCV)ribonucleic acid (RNA)\<25 IU/mL(target not detected)12 weeks after last planned dose of study medication;Relapse:HCV RNA =\>25 IU/mL during follow-up period after previous HCV RNA\<25 IU/mL at planned end of treatment(EOT)\[Week 24 or Week 48\] and participant did not achieve SVR12planned;On treatment virologic failure:meeting virologic stopping rule and/or having detectable HCV RNA at EOT with viral breakthrough(having a confirmed increase \>1 log 10 in HCV RNA level from the lowest level reached or confirmed value of HCV RNA \>100 IU/mL in participants whose HCV RNA has previously become \<25 IU/mL during treatment).Stopping rule defined as HCV RNA value \>1000 IU/mL at Week 4, 8 or 12 or detectable HCV RNA at Week 24, 32 or 40;Other:HCV RNA \<25 IU/mL at actual EOT and never HCV RNA =\>25 IU/mL thereafter.
Time frame: From Day 1 (Baseline) up to Follow-up visit (Week 36 or Week 60)
The study was conducted at 5 sites in Russia.
| Milestone | Treatment-naïve | Treatment-experienced |
|---|---|---|
| Started | 16 | 20 |
| Completed | 15 | 19 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
A eRVR is defined as having hepatitis C virus (HCV) ribonucleic acid (RNA) less than 25 IU/mL, (target not detected) at Weeks 4 and 12 of treatment.
| Participants | Treatment-naïve | Treatment-experienced |
|---|---|---|
| Number of Participants With Extended Rapid Virologic Response (eRVR) | 13 | 18 |
Changes from baseline in log10 HCV RNA levels were calculated.
| Log 10 IU/mL | Treatment-naïve | Treatment-experienced |
|---|---|---|
| Baseline (n=16, 20) | 6.20 (4.6 to 6.9) | 6.10 (5.7 to 7.0) |
| Week 4 (n=16, 20) | -5.47 (-6.2 to -3.9) | -5.33 (-6.3 to -3.5) |
| Week 8 (n=16,19) | -5.50 (-6.2 to -3.9) | -5.39 (-6.3 to -5.00) |
| Week 12 (n=15,19) | -5.46 (-6.2 to -3.9) | -5.39 (-6.3 to -5.00) |
| Week 24 (n=14, 19) | -5.53 (-6.2 to -3.9) | -5.39 (-6.3 to -0.6) |
| Week 32 (n=2, 12) | -5.30 (-5.5 to -5.1) | -5.46 (-6.3 to -5.2) |
| Week 40 (n=2, 12) | -5.30 (-5.5 to -5.1) | -5.46 (-6.3 to -5.2) |
| Week 48 (n=2, 12) | -3.14 (-5.1 to -1.2) | -5.46 (-6.3 to -5.2) |
A RVR is defined as having hepatitis C virus (HCV) ribonucleic acid (RNA) less than 25 IU/mL, (target not detected) at Week 4
| Participants | Treatment-naïve | Treatment-experienced |
|---|---|---|
| Number of Participants With Rapid Virologic Response (RVR) at Week 4 | 14 | 18 |
The table below shows number of participants with HCV RNA Less than 25 IU/mL, (target not detected) at Weeks 8, 12, 24, 32, 40 and 48. Only 3 treatment-naive and 14 Treatment-experienced participants were assigned to receive study treatment after Week 24. Only participants still receiving Treatment were assessed at 32, 40, and 48 weeks.
| Participants | Treatment-naïve | Treatment-experienced |
|---|---|---|
| Week 8 (n=16, 20) | 16 | 19 |
| Week 12 (n=16, 20) | 15 | 19 |
| Week 24 (n=16, 20) | 15 | 18 |
| Week 32 (n=3, 14) | 2 | 12 |
| Week 40 (n=3, 14) | 2 | 12 |
| Week 48 (n=3, 14) | 1 | 12 |
Virologic failure is defined as hepatitis C virus (HCV) ribonucleic acid (RNA) levels more than 1,000 IU/mL at Weeks 4, 8, 12, 24, 32, or 40.
| Participants | Treatment-naïve | Treatment-experienced |
|---|---|---|
| Number of Participants With Virologic Failure | 1 | 2 |
Participants were evaluated for following 4 categories of treatment outcome;Sustained Virologic Response 12 Weeks After Last Planned Dose of Study Medication(SVR12):hepatitis C virus (HCV)ribonucleic acid (RNA)\<25 IU/mL(target not detected)12 weeks after last planned dose of study medication;Relapse:HCV RNA =\>25 IU/mL during follow-up period after previous HCV RNA\<25 IU/mL at planned end of treatment(EOT)\[Week 24 or Week 48\] and participant did not achieve SVR12planned;On treatment virologic failure:meeting virologic stopping rule and/or having detectable HCV RNA at EOT with viral breakthrough(having a confirmed increase \>1 log 10 in HCV RNA level from the lowest level reached or confirmed value of HCV RNA \>100 IU/mL in participants whose HCV RNA has previously become \<25 IU/mL during treatment).Stopping rule defined as HCV RNA value \>1000 IU/mL at Week 4, 8 or 12 or detectable HCV RNA at Week 24, 32 or 40;Other:HCV RNA \<25 IU/mL at actual EOT and never HCV RNA =\>25 IU/mL thereafter.
| Participants | Treatment-naïve | Treatment-experienced |
|---|---|---|
| SVR12 | 14 | 16 |
| Relapse | 0 | 1 |
| On treatment virologic failure | 1 | 2 |
| Other | 1 | 1 |
Collected over 60 weeks. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment-naïve | — | 0/16 (0%) | 16/16 (100%) |
| Treatment-experienced | — | 0/20 (0%) | 19/20 (95%) |
| Event | Treatment-naïve | Treatment-experienced |
|---|---|---|
| Influenza like illnessGeneral disorders | 6/16 | 9/20 |
| PyrexiaGeneral disorders | 6/16 | 3/20 |
| AnaemiaBlood and lymphatic system disorders | 6/16 | 6/20 |
| AstheniaGeneral disorders | 5/16 | 3/20 |
| PruritusSkin and subcutaneous tissue disorders | 4/16 | 2/20 |
| RashSkin and subcutaneous tissue disorders | 4/16 | 0/20 |
| NeutropeniaBlood and lymphatic system disorders | 2/16 | 4/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/16 | 0/20 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/16 | 1/20 |
| Alanine aminotransferase increasedInvestigations | 2/16 | 2/20 |
| Age, Customized(Participants) | Treatment-naïve | Treatment-experienced | Total |
|---|---|---|---|
| <= 45 years | 13 | 12 | 25 |
| Between 45 and 65 years | 2 | 8 | 10 |
| > 65 years | 1 | 0 | 1 |
| Sex: Female, Male(Participants) | Treatment-naïve | Treatment-experienced | Total |
|---|---|---|---|
| Female | 9 | 13 | 22 |
| Male | 7 | 7 | 14 |
The record gives a start of Jan 2012, a primary completion of Apr 2012 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telaprevir · Peginterferon alfa-2a · Ribavirin
Janssen-Cilag International NV →